To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.

开始日期2026-06-10

申办/合作机构

The University of Texas MD Anderson Cancer Center

NCT07286149

/ Not yet recruiting临床1/2期

KEYMAKER-U01 Substudy 01F: A Phase 1b/2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations

Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn:
* About the safety of MK-1084 and if people tolerate it when taken with other treatments
* How many people have the cancer respond (get smaller or go away) to the treatments

开始日期2026-02-23

申办/合作机构

Merck Sharp & Dohme LLC

[+1]

NCT07302841

/ Not yet recruiting临床4期IIT

A Clinical Study Evaluating the Efficacy and Safety of Tunlametinib in Combination With Chemotherapy and Cetuximab β in Patients With Advanced Pancreatic Cancer

This study is a prospective, open-label, single-arm clinical trial evaluating the safety and efficacy of tunlametinib in combination with gemcitabine/albumin-bound paclitaxel and an EGFR monoclonal antibody as first-line therapy in treatment-naive subjects with advanced pancreatic cancer.

开始日期2026-01-20

申办/合作机构

天津市肿瘤医院（天津医科大学肿瘤医院）

100 项与西妥昔单抗相关的临床结果

登录后查看更多信息

100 项与西妥昔单抗相关的转化医学

登录后查看更多信息

100 项与西妥昔单抗相关的专利（医药）

登录后查看更多信息

6,636

项与西妥昔单抗相关的文献（医药）

2026-12-01·MOLECULAR BIOLOGY REPORTS

Non-Coding RNAs and cernas: emerging modulators of drug response in colorectal cancer

Review

作者: Abkenar, Elahe Daskar ; Sadeghi, Amir ; Mojarad, Ehsan Nazemalhosseini ; Nobili, Stefania ; Shams, Elahe ; Moghani, Mona Malekzadeh ; Sina, Negin ; Ebrahimi, Sara ; Fatemi, Nayeralsadat

Colorectal cancer (CRC) is still one of the most common cancers and a leading cause of cancer morbidity worldwide. A significant issue that should be paid much attention to is its resistance to anticancer agents. Non-coding RNAs (ncRNAs), such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), have been identified as important regulators of drug response and drug resistance in CRC. In this review, we provide a comprehensive assessment of the studies conducted in the field of investigating the role of ncRNAs in drug resistance to prominent anticancer agents used in CRC, including 5-fluorouracil (5-FU), oxaliplatin, cetuximab, bevacizumab, and regorafenib. We focussed specifically on the miRNAs, lncRNAs, and circRNAs associated with resistance to each drug individually, even within the context of combination therapies, such as FOLFOX. We also reviewed competing endogenous RNA (ceRNAs) networks and their relationship with drug sensitivity and resistance and new therapeutic strategies to manage drug resistance in CRC and also analyzed the role of ceRNA networks in modulating drug response and its implications for new approaches to overcome drug resistance in CRC. This article also discusses findings from human clinical trials, highlighting evidence from patient studies that validate the role of targeting ceRNA and ncRNA networks in improving drug sensitivity, overcoming resistance, and enhancing therapeutic outcomes in CRC. It supports the targeting of ncRNA and ceRNA networks as potential therapies to improve treatment outcomes and drug resistance in CRC.

2026-03-01·Actas Dermo-Sifiliograficas

Eruptive Verrucous Keratoses and Melanocytic Nevi Induced by Encorafenib Plus Cetuximab in a Patient With Metastatic Colorectal Cancer

Article

作者: Ferreirinha, A ; Moura, C ; Garrido, P M

2026-02-01·COMPUTATIONAL BIOLOGY AND CHEMISTRY

LHRCDA: Predicting associations between circRNA and drug sensitivity via learnable hypergraph reconstruction

Article

作者: Wang, Xu ; Li, Mingxuan ; Song, Jinmiao ; Zhai, Hui ; Wang, Jingshuai

Circular RNAs (circRNAs) play key roles in the development of various diseases and drug responses, and mining their potential association with drugs is of great significance in unraveling disease mechanisms and discovering new therapeutic targets. However, traditional hypergraph methods typically rely on a static composition strategy, which makes it challenging to dynamically adjust the structure according to the task, resulting in a limited ability to extract higher-order information. Accordingly, we present a learnable hypergraph reconstruction (LHRCDA) approach for predicting circRNA-drug sensitivity associations. Specifically, the hypergraph representation is initialized based on matrix decomposition, followed by a learnable hypergraph reconstruction mechanism to adaptively capture potential higher-order structural information. After reconstruction, a hierarchical hypergraph mapping approach encodes the hypergraph at multiple levels, thereby further enhancing the ability to model complex nonlinear interactions between hyperedges. To effectively integrate different view representations from heterogeneous graph and hypergraph views, we adopt a hierarchical perceptual fusion strategy that solves the problem of information redundancy or loss that exists in traditional single fusion methods. Ultimately, the fused node representations are nonlinearly mapped using an MLP to output the association probabilities between circRNAs and drugs. Experimental results show that the hypergraph approach based on higher-order structural modeling outperforms multiple existing state-of-the-art models in circRNA-drug sensitivity association prediction. In addition, case studies were conducted on the drugs vorinostat and cetuximab, further demonstrating the potential of our model as an efficient and reliable tool.

1,370

项与西妥昔单抗相关的新闻（医药）

2026-01-14

·PRNewswire

AVEO Oncology, an LG Chem company, Announces First Patient Dosed in Front-Line AML Combination Study of Ficlatuzumab

– Collaboration with Blood Cancer United® in its Beat AML® Master Clinical Trial – – AVEO's ficlatuzumab compound to be studied in combination with azacitidine and venetoclax in patients with AML in a Phase 1b/2 clinical trial – – First patient dosed into the Phase 1b/2 clinical trial – BOSTON, Jan. 14, 2026 /PRNewswire/ -- AVEO Oncology, an LG Chem company, (AVEO) announced today that the first patient has been successfully dosed in a Phase 1b/2 clinical trial evaluating ficlatuzumab in combination with azacitidine and venetoclax in patients that are 60 years of age or older with untreated acute myeloid leukemia (AML) through a Master Clinical Trial Collaboration Agreement with Blood Cancer United®, formerly the Leukemia & Lymphoma Society. As part of this strategic collaboration with Blood Cancer United, a global nonprofit focused on blood cancer patient support, research, and advocacy, Blood Cancer United will be sponsoring the clinical trial as a sub-study in their Beat AML® Master Clinical Trial, the first collaborative precision medicine clinical trial in a blood cancer, which tests multiple therapies in multiple study arms simultaneously. The Phase 1b/2 clinical trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination as a potential treatment for AML. Ficlatuzumab is AVEO's investigational humanized IgG1 monoclonal antibody that is designed to bind to the hepatocyte growth factor (HGF) ligand and prevent it from signaling via the c-Met receptor. Early phase clinical trials evaluating ficlatuzumab in combination with cytarabine in AML reported a favorable safety profile with promising clinical activity, supporting ficlatuzumab for further study in AML patients, particularly in those who are considered unfit for standard intensive first-line therapy. "This is a significant milestone for AVEO and Blood Cancer United, who are both dedicated to improving patient outcomes through novel clinical research," said Michael P. Bailey, President and CEO of AVEO. "We welcome this partnership and are excited to collaborate on this important clinical trial as we continue to expand our efforts to address high unmet medical needs with our novel clinical stage portfolio of therapies." "The Beat AML Master Clinical Trial seeks to change the paradigm for how this deadly cancer is treated, using an innovative precision medicine protocol and implementing strategic partnerships," said Lore Gruenbaum, Ph.D, Chief Scientific Officer of Blood Cancer United. "Our collaboration with AVEO is a key next step for the trial and transforming patient care for adults with AML." About AVEO Pharmaceuticals, Inc. AVEO Pharmaceuticals, Inc., an LG Chem company, (AVEO) is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO and its strategic partners continue to develop FOTIVDA in other novel targeted combinations in RCC. The company also has investigational programs in other areas of high unmet need, including ficlatuzumab in HPV-negative refractory head and neck squamous cell carcinoma and rilogrotug (also known as AV-380) in cancer cachexia. AVEO became a wholly owned subsidiary of LG Chem Life Sciences USA, Inc. on January 19, 2023. AVEO continues to operate under the AVEO Oncology, an LG Chem company, name. About LG Chem, Ltd. and LG Chem Life Sciences LG Chem is a leading global chemical company with a diversified business portfolio spanning across petrochemicals, advanced materials, and life sciences. LG Chem Life Sciences, the life sciences business division of LG Chem, is dedicated to developing and delivering innovative medicines across a broad range of therapeutic areas. Guided by its mission to transform people's lives through inspiring science and leading innovation, LG Chem Life Sciences is offering differentiated solutions to its customers. For more information, please visit . About Blood Cancer United® and the Beat AML® Master Clinical Trial Blood Cancer United (formerly The Leukemia & Lymphoma Society) is the largest global nonprofit focused on blood cancer patient support, research, and advocacy. The organization's mission is to cure blood cancer and improve the quality of life of all patients and their families. To achieve it, Blood Cancer United brings together a community of people—patients and their families, volunteers, healthcare providers, scientists, staff, partners, fundraisers, and philanthropists—who believe all blood cancer patients deserve longer, fuller lives. For support and to learn more, visit . The Beat AML® Master Clinical Trial (NCT03013998), launched in 2016 by Blood Cancer United, is the first collaborative precision medicine clinical trial in a blood cancer. The trial uses advanced genomic technology to match patients to the most promising targeted treatment based on their unique genetic mutations. The trial tests multiple therapies in multiple sub-studies simultaneously and has already generated strong results, demonstrating positive survival rates and better quality of life. Over the past decade, Beat AML has grown into a powerful ecosystem of pharma companies, genetic testing experts, data specialists, regulatory agencies, and other industry partners working toward better and safer treatments for patients with AML. For more information, visit . About Ficlatuzumab Ficlatuzumab (formerly known as AV-299) is a potent hepatocyte growth factor (HGF) immunoglobulin G1 inhibitory antibody that binds to the HGF ligand with high affinity and specificity. HGF is the natural ligand of c-Met and blocking HGF inhibits signaling through the HGF/c-Met signaling pathway. The U.S. Food and Drug Administration designated as a Fast Track development program the investigation of ficlatuzumab and ERBITUX® (cetuximab) for relapsed/recurrent HNSCC in September 2021, which is currently in a Phase 3 clinical study. Contacts Media: John F. Kouten JFK Communications, Inc. 908-227-4714 [email protected] SOURCE AVEO, an LG Chem company 21% more press release views with Request a Demo

临床3期快速通道

2026-01-13

·网易号

无惧“癌王”！中国药企领跑KRAS G12D赛道，全线疗效告捷

作者：Tony多年来，KRAS一直被视为“不可成药”的靶点。由于KRAS蛋白表面光滑，难以找到让小分子药物结合并起效的“口袋”，因此药物开发难度极大。不过，随着科研与制药领域的不断突破，针对KRAS G12C突变的药物已陆续问世，目前全球有五款相关药物获批。在我国，氟泽雷塞（信达/劲方）、格索雷塞（正大天晴/益方）和戈来雷塞（艾力斯/加科思）三款获批药物均已进入医保，战场也正在从后线前移到一线联合的新赛道。而在KRAS突变家族中，G12D是更为常见的亚型之一，约占所有KRAS突变癌症的28%，在胰腺癌、结直肠癌、肺腺癌等实体瘤中均有较高发生率[1]，这也使其成为更具吸引力的治疗靶点。来源：包图网1G12D和G12C有什么区别？KRAS基因突变多数发生在密码子12位点，如G12D、G12C和G12V等。简单来说，如果KRAS基因是维持细胞正常生长和分裂的“齿轮”，那它们则是“卡住齿轮”、导致癌细胞疯狂生长的不同“故障”类型。虽然结果相似，但针对不同“故障”的药物研发难度和策略却大不相同：G12C突变：KRAS蛋白表面很光滑，这个突变在KRAS蛋白表面创造了一个特殊的“把手”——半胱氨酸。现有的G12C靶向药的研发逻辑就像是设计了一把特制的“钳子”，可以精准地抓住这个“把手”，帮助“齿轮”恢复正常运转。G12D突变：相比之下，G12D突变的蛋白表面更加“光滑”，没有现成的“半胱氨酸把手” 供药物直接、牢固地结合。就像面对一块光滑的玻璃，很难找到施力点去抓取。这种结构差异，使得G12D靶向药物的研发难度更高，药物设计需要“另辟蹊径”，例如通过变构调节或间接作用机制实现抑制。尽管挑战巨大，但KRAS G12D突变因在实体瘤中较高的发生率，患者群体规模高于G12C突变，这庞大的临床需求，推动该靶点成为全球新药研发的“必争之地”。目前，虽然尚未有G12D靶向药获批，但全球在研药物已超过60款，未来激烈的竞争格局已初步显现。同时再强调一下，胰腺癌、结直肠癌乃至肺腺癌患者，一定要在基因检测报告中看看是否有“KRAS G12D突变”——这很可能意味着，将有机会用上针对该突变的最新靶向药物。2谁会先攻克G12D？目前在KRAS G12D靶向药研发这场竞速中，进度最快的两款候选药物均来自中国。其一是劲方医药的GFH375（VS-7375）氟泽雷塞（GFH925）是在我国获批的第一个G12C靶向药，就是由劲方医药研发的，目前正在探索与西妥昔单抗（EGFR单抗）联用在一线治疗的可能性。GFH375聚焦的则是G12D，通过非共价形式结合KRAS G12D蛋白，阻断其向细胞发送“持续生长”的错误信号，从而有效抑制肿瘤增殖。2025年ESMO会议公布了GFH375在胰腺癌中展现的惊艳疗效[2]。注意，这可不是一线治疗胰腺癌的数据，其中70%的患者接受了三线及以上的治疗，且1/3的患者接受过PD-1/PD-L1等免疫治疗。患者的疾病控制率（DCR）为97%，仅有两人出现疾病进展；客观缓解率（ORR）为41%，这对于后线治疗胰腺癌来说无疑是令人振奋的。不过，胰腺癌素有“癌王”之称，患者整体身体状况往往较差。本次研究的无进展生存期（PFS）并不算惊艳，中位PFS为5.52个月。还值得一提的是，研究发现即便患者合并了SMAD4、TP53等胰腺癌中常见的“不良预后”基因突变，仍能从GFH375治疗中获益。特别是SMAD4共突变患者，ORR为83.3%，高于不携带该突变的患者，表明GFH375的疗效不受这些“坏基因”限制，可适用于更广泛群体。2025年11月，GFH375已正式启动首个III期临床试验，计划纳入320名既往接受过治疗的KRAS G12D突变型转移性胰腺癌患者，比较GFH375单药与标准化疗方案的有效性、安全性、耐受性。此外，2025年WCLC会议公布了GFH375在经治非小细胞肺癌（NSCLC）患者中的初步研究数据[3]。在28名接受治疗的NSCLC患者中（中位随访4.5个月），多个剂量组均已观察到肿瘤缓解。在26例可评估患者中，ORR为57.7%，DCR为88.5%。另一个是恒瑞医药的HRS-4642HRS-4642是由恒瑞医药自主研发的KRAS G12D抑制剂，能够特异性结合KRAS G12D，进而抑制MEK、ERK蛋白的磷酸化，发挥抗肿瘤作用。同样在2025年ESMO会议上[4]，HRS-4642联合吉西他滨和白蛋白紫杉醇（AG方案）一线治疗KRAS G12D突变胰腺癌的Ib/II期研究数据公开，30例患者ORR为60%，超半数患者肿瘤显著缩小，DCR达93.3%，没有患者因不良反应中止治疗。患者肿瘤缓解情况2025年10月，HRS-4642联合化疗一线治疗晚期胰腺癌的III期研究启动，这也是全球首个进入III期临床的KRAS G12D靶向药。还有这些药物值得关注此外，美国药企Revolution Medicines的RMC-9805（Zoldonrasib）和RMC-6236（Daraxonrasib）两款药物的疗效也比较惊艳。RMC-9805聚焦KRAS G12D，而且可以“瞄准”处于激活状态的G12D蛋白，在“驱动肿瘤的那一刻”抓住突变蛋白。早期数据显示，在18例可评估的KRAS G12D突变经治NSCLC患者中，ORR为61%，DCR为89%。RMC-6236则是“广谱”KRAS抑制剂，能够覆盖的KRAS突变更广，不单单是G12D。二线治疗中，ORR达到35%，DCR达到92%，中位PFS为8.5个月，中位OS为13.1个月；一线联合吉西他滨和白蛋白紫杉醇，ORR为55%，DCR为90%。目前该药物也已经进入Ⅲ期临床。不过，就“广谱”KRAS抑制剂来看，RMC-6236走的路线和其它药物的路线也不太一样。RMG-6236本质上一个分子胶，能够将处于激活状态的KRAS蛋白与人体内的亲环素A“粘合”在一起，从而间接抑制其功能，而非直接阻断KRAS蛋白本身。其他如礼来、辉瑞、百济神州等药企选择的则是小分子抑制剂路线。比如加科思的小分子“广谱”KRAS抑制剂JAB-23E73，不依赖于KRAS第12位氨基酸的相互作用，而是通过和KRAS其他位置的相互作用，所以能对不同突变的KRAS有效。同时，相较于分子胶路线较高的皮疹与黏膜炎发生率，小分子抑制剂路线在早期临床中展现的安全性优势更明显。3如何用上KRAS G12D治疗药物？目前针对G12D突变和“广谱”KRAS抑制剂的临床试验正在推进中，距离药物上市还需要“让子弹飞一会儿”。不过，符合条件的患者可以通过参与相关临床试验，提前获得新药治疗的机会。1. 明确是否属于KRAS G12D突变实体瘤？关键是要进行基因检测。可以通过肿瘤组织（手术或穿刺标本）或血液样本进行检测。2. 不同的临床试验对患者的要求往往不同，且会根据研究进展动态调整。通常情况下，需满足以下基本条件：治疗经历：初治患者，或经标准治疗后病情进展的患者。需注意的是，在接受标准治疗方案前盲目尝试其他非规范治疗，可能会影响参与临床试验的资格。体能状况：患者一般应能够自理，日常活动能力良好（通常对应ECOG评分0-1分）。健康状况：肝、肾及造血功能基本正常，能满足试验要求。3. 从已公布的临床数据来看，G12D靶向药的治疗副作用较为可控。常见如消化道反应（恶心、腹泻等）、血液指标变化（中性粒细胞减少、血小板降低等）、肝功能异常（转氨酶升高等），这些副作用大多可通过剂量调整或辅助治疗进行管理，多数患者能够耐受。4.如何找到适合自己的临床试验？咨询主治医生。主治医生最了解患者目前的情况，能判断是否符合临床试验，并可能协助联系研究团队。医院官方渠道。大型医院或肿瘤专科医院通常设有本院正在开展的临床试验信息，可关注官网或官方公众号了解。权威渠道。还可以通过这些正规渠道，获得关于临床试验的详细信息：国家药监局药物临床试验登记与信息公示平台（http://www.chinadrugtrials.org.cn/）、中国临床试验注册中心（http://www.chictr.org.cn/）、全球临床试验数据库(https://www.clinicaltrials.gov/)。药企官网。一般大型药企会在官网或官方微信公众号公布在研项目及招募信息，尤其针对新药或创新疗法的试验。患者社群组织。患者社群、病友群或相关公益组织也会分享临床试验资讯，但需要核实信息真实性，避免误信虚假宣传。5.患者是否能参加国外的临床试验？临床试验通常对全球患者开放，不限制国籍。但一般需要满足：完全符合该试验的入组标准；试验中心有名额且正在招募；患者能够在国外完成全部治疗与定期随访；经评估，参与试验对患者具有潜在的临床获益（如患者已处于终末期、无法自理或体能状况较差，则可能不适合参与）。4KRAS战场远未到终局。G12C的战况逐渐分明，G12D的炮火才刚刚上膛，未来还会有更多靶点（如G12V、G13D等）的新武器将陆续登场。从“不可成药”的标签，到一步步构筑“癌症之王并非不可战胜”的信心，请相信，医学的脚步从未停歇，每一个“不可能”都在被持续改写！我们将持续关注并传递KRAS 治疗领域的最新进展，期待更多生命的好消息早日到来。图片来源：包图网参考文献[1]Tamara Isermann, et al. KRAS inhibitors: resistance drivers and combinatorial strategies. Trends Cancer. 2025 Feb;11(2):91-116.[2]ZhouA,LiZ,SunY,etal.EfficacyandsafetyofGFH375monotherapyinpreviouslytreatedadvancedKRASG12Dmutantpancreaticductaladenocarcinoma(PDAC).Presentedat:2025ESMOCongress;October17-21,2025;Berlin,Germany.Abstract:LBA84[3]Z. Li, et al. Efficacy and Safety of GFH375 in Advanced Non-small Cell Lung Cancer Patients with KRAS G12D Mutation. 2025 WCLC Abstract MA02.07.[4]Wang, L., et al. ESMO 2025 Oral presentation 2215O.与癌共舞公众号及网站及APP上发表的文章及讨论仅代表作者或发帖人个人观点，不代表平台立场。与癌共舞公众号文章经医学编辑和版主审核，具有明显谬误和不良引导的文章将禁止发表。

2026-01-13

·北京医学感染与传染研究

柳叶刀胃肠病学与肝病学 11卷 1-2期

THE LANCET Gastroenterology & Hepatology. Volume 11Number1 柳叶刀胃肠病学与肝病学 11卷 1期 https://www.thelancet.com/journals/langas/issue/current EDITORIAL(社论) 1 Accelerating MASH trials: from biopsy to biomarkers 加速MASH（代谢障碍相关脂肪性肝炎）试验：从活检到生物标志物 The Lancet Gastroenterology & Hepatology The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p1 COMMENT（述评） 2 Optimising treatment in Crohn's disease: is the main issue early versus late or biologic naive versus biologic experienced? 优化克罗恩病的治疗：主要问题在于早期治疗与晚期治疗，还是生物制剂初治患者与生物制剂经治患者？ Marte Lie Høivik The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p2 3 Ileal bile acid transporter inhibitors for cholestatic pruritus in primary biliary cholangitis 针对原发性胆汁性胆管炎中胆汁淤积性瘙痒的回肠胆汁酸转运蛋白抑制剂 Ansgar W Lohse,David N Assis The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p3 4 Dual targeting of TNF and IL-23 by a bispecific antibody in ulcerative colitis 双特异性抗体在溃疡性结肠炎中同时靶向TNF和IL-23 Raja Atreya,Markus F Neurath The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p5 5 The essential medicines list for inflammatory bowel disease: time to raise the standards of global care 炎症性肠病基本药物清单：是时候提高全球护理标准了 Nanne K de Boer,Richard B Gearry,Charles N Bernstein,Rupa Banerjee,David T Rubin,Gilaad G Kaplanon behalf of the Globalization Cluster of the International Organization of IBD The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p7 NEWS（新闻） 6 The Liver Meeting 2025 2025年肝脏会议 Rob Brierley The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p10 IN FOCUS（焦点） 7 Food Matters 食物很重要 Dietary management of constipation: time for clinical guidelines to catch up with evidence 便秘的饮食治疗：是时候让临床指南跟上证据的步伐了 Eirini Dimidi,Kevin Whelan The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p11 ARTICLES（论著） 8 Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study 维多珠单抗在早期和晚期克罗恩病中的应用（LOVE-CD）：一项4期开放性队列研究 Geert R D'Haens,Mark Löwenberg,Filip Baert,Peter Bossuyt,Tamás Molnár,Frank Hoentjen,Esmé Clasquin,Krisztina B Gecse,Melanie S Hulshoff,Gert De Hertogh,Matthias Lenfant,Lotte Oldenburg,Séverine Vermeire The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p12 9 Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): 利尼西巴特治疗原发性胆汁性胆管炎和胆汁淤积性瘙痒患者（GLISTEN）：一项随机、多中心、双盲、安慰剂对照的3期试验 a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Gideon M Hirschfield,Christopher L Bowlus,David E J Jones,Andreas E Kremer,Marlyn J Mayo,Atsushi Tanaka,Pietro Andreone,Jidong Jia,Qinglong Jin,Ricardo U Macías-Rodríguez,Alexander R Cobitz,Brooke M Currie,Ciara Gorey,Ivana Lazic,Danielle Podmore,Andrea Ribeiro,Jennifer B Shannon,Brandon Swift,Megan M McLaughlin,Cynthia Levyfor the GLISTEN Study Group The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p22 10 Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial SOR102（一种口服双特异性肿瘤坏死因子和白细胞介素-23抑制剂）在健康受试者和溃疡性结肠炎患者中的安全性和药代动力学：一项首次人体、双盲、随机、安慰剂对照的1期试验 Vipul Jairath,Silvio Danese,Geert R D’Haens,Brian G Feagan,Laurent Peyrin-Biroulet,Bruce E Sands,Ingrid Gaemers,Matt Westfall,Allyson Q Terry,Kevin J Roberts,Sara Barbat,Pamela Wedel,Jacqueline M Benson,Carlos Sattler The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p34 11 Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial 西洛芬酸在非肝硬化原发性硬化性胆管炎中的应用（PRIMIS）：一项随机、双盲、多中心、安慰剂对照的3期试验 Michael Trauner,Cynthia Levy,Atsushi Tanaka,Zachary Goodman,Douglas Thorburn,Deepak Joshi,Kimmo Salminen,Kidist Yimam,Hiroyuki Isayama,Aldo J Montano-Loza,Stephen Caldwell,Mark Danta,Martti Farkkila,Juan F Gallegos-Orozco,Stuart C Gordon,Holger Hinrichsen,Pietro Invernizzi,Raj Vuppalanchi,Kaiyi Zhu,Jun Xu,Xiangyu Liu,Xiaomin Lu,Gerald Crans,Shahla Bolbolan,Lisa Boyette,Muhsen Alani,William T Barchuk,Timothy R Watkins,Mark C Genovese,Christopher L Bowlus The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p46 REVIEW（综述） 12 Age-related changes of the gastrointestinal tract 胃肠道的年龄相关变化 Alberto Pilotto,Carlo Custodero,Lucilla Crudele,Wanda Morganti,Nicola Veronese,Marilisa Franceschi The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p59 13 Fatigue in people with primary biliary cholangitis: a position paper from the European Reference Network for Rare Liver Diseases 原发性胆汁性胆管炎患者的疲劳问题：欧洲罕见肝病参考网络立场文件 Ozgur M Koc,Anne-Kristin Toussaint,Aurelie Untas,Piotr Milkiewicz,Henriette Ytting,Laura Buck,David E Jones,Gideon Hirschfield,Angela Leburgue,Christoph Schramm,Frederik Nevens,Adriaan J van der Meer,Alessio Gerussi,Jef Verbeek The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p71 THE LANCET Gastroenterology & Hepatology. Volume 11Number2 柳叶刀胃肠病学与肝病学 11卷 2期 https://www.thelancet.com/journals/langas/issue/current EDITORIAL(社论) 1 ACIP's HBV birth-dose vaccine recommendations: a fiasco 美国免疫接种咨询委员会（ACIP）的乙肝疫苗出生剂量推荐：一场闹剧 The Lancet Gastroenterology & Hepatology The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p87 COMMENT（述评） 2 Expanding the therapeutic arsenal for paediatric ulcerative colitis 扩充儿童溃疡性结肠炎的治疗武器库 Stephanie A Vuijk,Esmée H Boute,Lissy de Ridder The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p88 3 Closing the Middle East and north Africa representation gap in clinical trials in inflammatory bowel disease 缩小炎症性肠病临床试验中中东和北非地区代表不足的差距 Mohammad Shebab,Ahmed Al-Hindawi,Shane W Goodwin,Yuhong Yuan,Talat Bessissow,Laurent Peyrin-Biroulet,Vipul Jairath The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p89 4 Colorectal cancer screening in LGBTQIA+ people: an urgent call for equity 对LGBTQIA+人群进行结直肠癌筛查：迫切呼吁公平 Vidhi Singh,Jayraan Badiee,Alexander Goldowsky,David Russo,Folasade P May The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p91 CORRESPONDENCE（读者来信） 5 Efficacy differentiation of sterile faecal filtrates in Clostridioides difficile infection 无菌粪便滤液在艰难梭菌感染中的疗效差异 Stefan Schreiber,Philip Rosenstiel,Stephan J Ott,Georg H Waetzig The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p94 6 Efficacy differentiation of sterile faecal filtrates in Clostridioides difficile infection – Authors’ reply 无菌粪便滤液在艰难梭菌感染中的疗效差异——作者回复 Dina Kao,Huiping Xu,Thomas Louie The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p94 7 Endoscopic palliation of malignant gastric outlet obstruction: harmonising outcomes 恶性胃出口梗阻的内镜下姑息治疗：统一疗效标准 Zachary L Smith The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p95 8 Clinical remission in ulcerative colitis: restoring precision in trial terminology 溃疡性结肠炎的临床缓解：恢复试验术语的精确性 Sailish Honap,Vipul Jairath,Fernando Magro,Silvio Danese,Laurent Peyrin-Biroulet The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p96 CORRECTIONS（更正） 9 Correction to Lancet Gastroenterol Hepatol 2019; 4: 364–75 对《柳叶刀-胃肠病学与肝病学》2019年；4卷：364-75页的更正 The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：e1 10 Correction to Lancet Gastroenterol Hepatol 2025; 10: 431–41 对《柳叶刀-胃肠病学与肝病学》2025年；10卷：431-41页的更正 The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：e1 NEWS（新闻） 11 Research in Brief 研究简讯 Holly Baker The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p98 IN FOCUS（焦点） 12 Patient Perspectives 患者视角 The label of a diagnosis 诊断标签 Cheryl Reeves The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p99 ARTICLES（论著） 13 Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial Mirikizumab治疗中重度活动性溃疡性结肠炎儿童患者的疗效和安全性（SHINE-1）：一项多中心、开放标签、非随机2期试验 Jess L Kaplan,Athos Bousvaros,Dan Turner,Marla Dubinsky,Amy Larkin,Jordan Johns,Yuki Otani,Wallace Crandall,Wendy J Komocsar,Jeffrey S Hyams The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p100 14 Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials Glecirasib联合或不联合西妥昔单抗治疗既往接受过治疗的KRASG12C突变局部晚期或转移性结直肠癌（JAB-21822-1002和JAB-21822-1007）：两项开放标签、非随机1/2期试验 Jian Li,Zhenghang Wang,Jing Huang,Yi Ba,Baoshan Cao,Suxia Luo,Wenhua Li,Chunmei Bai,Zhengbo Song,Jianping Xiong,Liangjun Zhu,Guangyu An,Yanqiao Zhang,Zhihua Li,Yongsheng Li,Yanhong Gu,Changlu Hu,Xingya Li,Chenghui Huang,Qihan Fu,Xianli Yin,Xinjun Liang,Diansheng Zhong,Huaqiu Shi,Xiaoyan Li,Zhen Li,Lian Liu,Feng Wang,Rong Liang,Guohao Xia,Zhen Wang,Andrea Wang-Gillam,Yuli Ding,Zhiyue Rao,Wenhui Pan,Shuang Lu,Xin Sun,Lin Shen The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p110 15 Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial 卡瑞利珠单抗联合卡培他滨辅助治疗中国肝内胆管癌术后患者（ACC）：一项单臂、单中心、开放标签、2期试验 Zheng Wang,Lixing Li,Peiran Huang,Honghu Tu,Xiangyu Zhang,Lei Yu,Fei Liang,Cheng Huang,Shuangjian Qiu,Qinghai Ye,Zhenbin Ding,Xiaowu Huang,Yinghong Shi,Kang Song,Huichuan Sun,Xiaoying Wang,Yongfeng Xu,Yao Yu,Qiang Gao,Lan Zhang,Jia Fan,Jian Zhou The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p124 16 Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial Tinengotinib治疗晚期或转移性胆管癌成人患者：一项多中心、开放标签、2期试验 Milind Javle,Christos Fountzilas,Chih-Yi Liao,Meredith Pelster,Daneng Li,Dustin Deming,Vaibhav Sahai,Lionel Kankeu Fonkoua,Allen Cohn,Parvez Mantry,Donald Richards,Edwin Kingsley,Frank Wu,Peng Peng,Katie Hennessy,Hui Wang,Caixia Sun,Shumao Ni,Jean Fan,Amit Mahipal The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p137 REVIEW（综述） 17 Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis 代谢功能障碍相关脂肪性肝炎当前及新兴治疗格局 Wenhao Li,William Alazawi,Rohit Loomba The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p150 VIEWPOINT（观点） 18 Ulcerative colitis: moving beyond the mucosal dogma 溃疡性结肠炎：超越黏膜教条 Elisabeth Eggermont,Krisztina Gecse,Noa Krugliak Cleveland,Frauke Petersen,João Sabino,AndréD'Hoore,Torsten Kucharzik,Mariangela Allocca,Gabriele Bislenghi,Kerri Novak,Gert De Hertogh,Christian Maaser,Bram Verstockt The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p163

100 项与西妥昔单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03455	西妥昔单抗	L01XC06	DB00002

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
BRAF V600E突变结直肠癌	中国	Merck Europe BV	2025-09-30
RAS 野生型结直肠癌	澳大利亚	Merck Healthcare Pty Ltd.	2007-09-25
头颈部肿瘤	美国	Eli Lilly & Co.	2006-03-01
转移性结直肠癌	欧盟	Merck Europe BV	2004-06-29
转移性结直肠癌	冰岛	Merck Europe BV	2004-06-29
转移性结直肠癌	列支敦士登	Merck Europe BV	2004-06-29
转移性结直肠癌	挪威	Merck Europe BV	2004-06-29
头颈部鳞状细胞癌	欧盟	Merck Europe BV	2004-06-29
头颈部鳞状细胞癌	冰岛	Merck Europe BV	2004-06-29
头颈部鳞状细胞癌	列支敦士登	Merck Europe BV	2004-06-29
头颈部鳞状细胞癌	挪威	Merck Europe BV	2004-06-29
结直肠癌	瑞士	Merck & Co., Inc.	2003-12-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
结肠癌	临床3期	美国	Merck Sharp & Dohme LLC	2025-07-16
结肠癌	临床3期	中国	Merck Sharp & Dohme LLC	2025-07-16
结肠癌	临床3期	日本	Merck Sharp & Dohme LLC	2025-07-16
结肠癌	临床3期	阿根廷	Merck Sharp & Dohme LLC	2025-07-16
结肠癌	临床3期	澳大利亚	Merck Sharp & Dohme LLC	2025-07-16
结肠癌	临床3期	巴西	Merck Sharp & Dohme LLC	2025-07-16
结肠癌	临床3期	芬兰	Merck Sharp & Dohme LLC	2025-07-16
结肠癌	临床3期	法国	Merck Sharp & Dohme LLC	2025-07-16
结肠癌	临床3期	德国	Merck Sharp & Dohme LLC	2025-07-16
结肠癌	临床3期	中国香港	Merck Sharp & Dohme LLC	2025-07-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04349267 (CTgov)	临床1/2期	晚期恶性实体瘤	44	BMS-986315 (Part 1A BMS-986315-80 mg)	醖艱衊鬱網積鏇蓋艱憲 = 醖衊衊夢壓製鏇鹽獵壓鏇觸願繭範築齋網製鑰 (醖顧夢糧獵艱獵築窪膚, 簾蓋艱夢鹽網網衊製憲 ~ 衊壓夢糧遞鏇選窪鏇鹽) 更多	-	2025-12-17
				BMS-986315 (Part 1A BMS-986315-200 mg)	醖艱衊鬱網積鏇蓋艱憲 = 築蓋鹹齋夢膚鬱顧蓋淵鏇觸願繭範築齋網製鑰 (醖顧夢糧獵艱獵築窪膚, 鑰顧餘膚築襯齋觸遞廠 ~ 醖蓋遞觸鏇鑰蓋鑰鏇構) 更多
ESMO_ASIA2025	N/A	RAS 野生型结直肠癌一线	969	Panitumumab	衊餘憲範廠觸壓襯壓憲(壓範餘膚鹹顧艱鬱鏇夢) = 襯齋範艱廠製窪顧憲齋網膚構顧糧鑰範醖鏇簾 (範遞鬱製簾鑰齋顧蓋繭, 23.68 ~ 38.12) 更多	积极	2025-12-05
				Cetuximab	衊餘憲範廠觸壓襯壓憲(壓範餘膚鹹顧艱鬱鏇夢) = 壓夢繭醖淵鑰餘觸獵選網膚構顧糧鑰範醖鏇簾 (範遞鬱製簾鑰齋顧蓋繭, 25.17 ~ 31.36) 更多
CeRWIN (ESMO_ASIA2025)	N/A	头颈部鳞状细胞癌 EGFR	136	Biosimilar cetuximab (alone or with chemotherapy/radiotherapy)	網襯餘顧廠鏇艱選鏇鬱(簾選夢選繭製鹹廠憲廠) = 簾構鹽積鬱鏇窪鹽製艱遞膚願窪願繭襯鹽膚選 (艱鑰鹽願膚憲網壓築鬱 ) 更多	积极	2025-12-05
ESMO_ASIA2025	N/A	RAS 野生型结直肠癌	101	Cetuximab + standard therapy	顧鏇衊簾鹽壓淵遞願積(鑰遞夢艱艱鏇艱窪蓋願) = 顧繭鏇鏇壓壓淵廠膚蓋範餘壓繭繭醖願顧窪鏇 (膚繭餘範鹹顧齋壓襯鏇 ) 更多	积极	2025-12-05
				Cetuximab + standard therapy (left-sided mCRC)	顧鏇衊簾鹽壓淵遞願積(鑰遞夢艱艱鏇艱窪蓋願) = 夢夢選糧艱獵鹹鹽糧繭範餘壓繭繭醖願顧窪鏇 (膚繭餘範鹹顧齋壓襯鏇 ) 更多
NCT04607421 (BREAKWATER, ESMO_ASIA2025)	临床3期	BRAF V600E突变结直肠癌一线 BRAF V600E-mutant	225	Encorafenib + cetuximab	構膚製築築遞蓋醖鹽網(鑰廠簾簾餘憲鬱鬱夢蓋) = 窪齋膚餘夢範鏇構鬱窪願憲願鬱鑰憲築齋積繭 (積構鬱醖獵積艱構齋獵, 4.1 ~ 16.1) 更多	积极	2025-12-05
				Encorafenib + cetuximab + mFOLFOX6	構膚製築築遞蓋醖鹽網(鑰廠簾簾餘憲鬱鬱夢蓋) = 淵窪糧蓋衊積醖鹹醖簾願憲願鬱鑰憲築齋積繭 (積構鬱醖獵積艱構齋獵, 13.9 ~ NE) 更多
NCT05291156 (CAVE-2 GOIM, Pubmed \| Ann Oncol)	临床2期	转移性结直肠癌 RAS \| BRAF	156	Cetuximab + Avelumab	淵窪壓糧窪製鹹衊鹹繭(願鬱鹽願艱蓋網襯糧網) = 齋範壓窪鑰醖醖顧範醖鏇構膚構醖壓鬱獵壓觸 (艱獵醖網衊願製顧壓鏇, 12.1 ~ 18.3) 更多	不佳	2025-12-01
				Cetuximab	淵窪壓糧窪製鹹衊鹹繭(願鬱鹽願艱蓋網襯糧網) = 廠構憲衊網夢鏇獵繭膚鏇構膚構醖壓鬱獵壓觸 (艱獵醖網衊願製顧壓鏇, 11 ~ NE) 更多
NCT05019534 (Pubmed \| J Transl Med)	临床1期	BRAF V600E突变结直肠癌二线 BRAF V600E \| microsatellite stable (MSS)	12	Vemurafenib+cetuximab+camrelizumab	構糧壓壓醖鹹鏇遞餘範(鏇糧鏇鹹顧構夢淵製壓) = 築廠壓淵窪網繭膚齋齋鹹淵網艱壓鏇顧製鹽憲 (壓範夢淵遞窪鹹選遞糧 ) 更多	积极	2025-11-12
NCT01302834 (RTOG 1016, ESMO2025)	临床3期	HPV16阳性口咽癌 p16-positive	805	Cisplatin with IMRT	膚鹹獵襯製觸網網鏇鏇(窪願網糧鹹鏇鬱鬱淵獵) = 積餘築餘衊窪糧願齋壓淵壓鏇醖鹹齋膚築選衊 (製壓壓蓋衊窪淵鹽衊築 ) 更多	不佳	2025-10-17
				Cetuximab with IMRT	膚鹹獵襯製觸網網鏇鏇(窪願網糧鹹鏇鬱鬱淵獵) = 憲觸構蓋餘願餘顧艱鏇淵壓鏇醖鹹齋膚築選衊 (製壓壓蓋衊窪淵鹽衊築 ) 更多
ESMO2025	N/A	转移性头颈部鳞状细胞癌二线	78	Carboplatin+Paclitaxel+Cetuximab	顧獵膚餘選觸鬱鏇積醖(壓廠衊淵襯積製壓夢鬱) = 選艱憲醖簾願鹹獵夢鹽鑰糧衊製艱範願壓壓選 (鹽遞鹽觸選襯衊艱觸獵 ) 更多	积极	2025-10-17
				Carboplatin+Paclitaxel+Cetuximab (immunotherapy alone (IO-A))	顧獵膚餘選觸鬱鏇積醖(壓廠衊淵襯積製壓夢鬱) = 壓淵繭淵窪餘蓋鹽憲遞鑰糧衊製艱範願壓壓選 (鹽遞鹽觸選襯衊艱觸獵 ) 更多
NCT04607421 (BREAKWATER, ESMO2025)	临床3期	BRAF V600E突变结直肠癌一线 BRAF V600E-mutant	78	Encorafenib + cetuximab + mFOLFOX6	齋衊糧簾積齋鹹顧製遞(簾觸淵夢築築壓積繭顧) = 製淵齋艱醖願憲範製憲憲醖衊積餘衊積選醖鏇 (顧觸觸構觸醖積壓蓋鏇, 42.2 ~ 72.9) 更多	积极	2025-10-17
				Control (chemotherapy ± bevacizumab)	齋衊糧簾積齋鹹顧製遞(簾觸淵夢築築壓積繭顧) = 願簾願積築齋鬱壓鑰製憲醖衊積餘衊積選醖鏇 (顧觸觸構觸醖積壓蓋鏇, 23.0 ~ 50.8) 更多